pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
fda press·5h ago·1 min read
save

FDA grants emergency use authorization for Simparica TRIO to treat New World screwworm in dogs and puppies

Aug 13, 2026·read at fda press ↗RegulatoryPositive

The U.S. Food and Drug Administration issued an Emergency Use Authorization for Simparica TRIO, a chewable tablet containing sarolaner, moxidectin and pyrantel, to treat New World screwworm infestations in dogs and puppies.

Most U.S. dogs are at low risk, but those living in, traveling to, or returning from areas where the parasite has been identified-particularly parts of Texas, New Mexico, and some countries south of the border-should be closely watched for signs such as visible maggots or foul odors.

Veterinarians are urged to provide immediate care for any suspected cases, and the USDA maintains an online dashboard of confirmed detections. The FDA’s action adds another treatment option to help contain any potential spread.

source

This writeup was produced by pharmadog from original reporting by fda press.

Original headline: “FDA Issues Emergency Use Authorization for Drug to Treat New World Screwworm in Dogs and Puppies”

read at fda press ↗
667 words · retrieved 3h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

drugs
moxidectin5
topics
EpilepsyVaccines

related stories

  • 13h agoOpinion: How to disrupt the health misinformation business modelSTAT
  • Jul 23Chutes & Ladders—Biogen R&D vet gets in FormationFierce Biotech
  • Jun 2910 clinical trials to watch in the second half of 2026BioPharma Dive
  • Jun 26FDA Proposes Rule That Would Help Hold Foreign Tobacco Product Manufacturers Accountable, Protect Public Healthfda press
  • May 4STAT+: Biotech raises $42 million to run Huntington’s disease trialSTAT